| 曾 俊,谭利华,伍玉枝,郭杨钰,付秀根.TACE结合立体定向体部X-刀治疗肝癌的临床疗效研究[J].现代生物医学进展英文版,2018,(13):2469-2472. |
| TACE结合立体定向体部X-刀治疗肝癌的临床疗效研究 |
| Effect of TACE Combined with Stereotactic Body X- knife on the Patients with Hepatocellular Carcinoma |
| Received:February 01, 2018 Revised:February 23, 2018 |
| DOI：10.13241/j.cnki.pmb.2018.13.014 |
| 中文关键词: 原发性肝癌 X-刀 经肝动脉化疗栓塞 临床疗效 |
| 英文关键词: Primary liver cancer X- knife TACE Clinical efficacy |
| 基金项目:湖南省社会发展领域科技支撑计划项目(2015SF2020-4) |
|
| Hits: 519 |
| Download times: 299 |
| 中文摘要: |
| 摘要 目的：探讨经肝动脉化疗栓塞(transarterial chemoembolization，TACE)结合立体定向体部X-刀治疗肝癌的临床疗效和安全性。方法：选取2015年12月至2017年8月在我院接受治疗的原发性肝癌患者120例，并将其随机分为X-刀组、TACE组以及联合组，每组患者各40例。X-刀组患者给予单纯X-刀治疗，TACE组给予单纯TACE治疗，联合组给予X-刀联合TACE治疗。观察并比较三组患者临床疗效、生存期、治疗前后肝功能的变化及治疗过程中毒副反应的发生情况情况。结果：联合组患者临床总有效率为47.5%，明显高于X-刀组和TACE组(P<0.05)；X-刀组患者临床总有效率为27.5%，显著高于TACE组(P<0.05)。X-刀组、TACE组、联合组患者生存时间分别为0.73±0.18年、0.48±0.18年、1.10±0.22年，联合组患者生存时间显著长于X-刀组和TACE组(P<0.05)，X-刀组患者生存时间长于TACE组(P<0.05)。三组患者治疗后血清血清谷丙转氨酶（alanine aminotransferase，ALT）、谷草转氨酶（aspartate aminotransferase，AST）、γ-谷胺酰转肽酶（Gamma - glutamyl transpeptidase，γ-GT）、总胆红素（total bilirubin，TBil水平与本组治疗前比较均显著降低(P<0.05)；联合组患者治疗后血清ALT、AST水平与TACE组和X-刀组比较差异均无统计学意义(P<0.05)，而血清γ-GT、TBil水平均显著低于TACE组和X-刀组(P<0.05)。三组患者毒副反应情况比较差异无统计学意义(P>0.05)。结论：TACE结合立体定向体部X-刀治疗肝癌的临床疗效明显优于单用TACE或X-刀治疗，且三种治疗方法的安全性相当。 |
| 英文摘要: |
| ABSTRACT Objective: To discuss the clinical efficacy and safety of transcatheter arterial chemoembolization(TACE) combined with stereotactic X- knife in the treatment of liver cancer. Methods: 120 patients with primary liver cancer were selected from December 2015 to August 2017 in our hospital. The patients were randomly divided into X- group, TACE group and combined group, each group had a total of 40 patients. X- knife group patients were treated with X- knife, TACE group was treated with TACE alone, and the combination group was treated with X- knife combined with TACE. The clinical effect, survival time, liver function before and after treatment and the occurrence of toxic side effects were compared among the three groups. Results: The total effective rate of combined group was 47.5%, which was significantly higher than that of the X-knife group and the TACE group (P<0.05). The total effective rate of X- knife group was 27. 5%, which was significantly higher than that of TACE group (P<0.05). The survival time of the combined group was (0.73±0.18) years, (0.48±0.18) years , (1.10±0.22) years, and the survival time of the combined group was significantly longer than that in the X - knife group and TACE group (P<0.05), the survival time of the X-knife group was longer than that in TACE group (P<0.05). The level of Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), Gamma - glutamyl transpeptidase (γ-GT) and total bilirubin (TBil) were significantly lower than those before treatment (P<0.05). The level of serum ALT and AST after treatment in the combined group were no significant difference with TACE group or X-knife group (P＞0.05), but the level of serum γ-GT and TBil was significantly lower than that of TACE group and X-knife group (P<0.05). There was no significant difference in the toxic and side effects among the three groups (P>0.05). Conclusion: The clinical efficacy of TACE combined with stereotactic X- knife is superior to TACE or X- knife alone in the treatment of liver cancer, and the safety of three treatments is equal. |
|
View Full Text
View/Add Comment Download reader |
| Close |
